Blake Borgeson Sells 30,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $3.25, for a total transaction of $97,500.00. Following the sale, the director owned 6,188,287 shares in the company, valued at $20,111,932.75. This represents a 0.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, July 7th, Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.96, for a total transaction of $158,400.00.
• On Tuesday, June 2nd, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.68, for a total transaction of $110,400.00.

Recursion Pharmaceuticals Price Performance

RXRX opened at $3.22 on Friday. The company has a fifty day simple moving average of $3.32 and a 200 day simple moving average of $3.45. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -3.10 and a beta of 1.03. Recursion Pharmaceuticals, Inc. has a twelve month low of $2.77 and a twelve month high of $7.18. The company has a current ratio of 5.03, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The firm had revenue of $7.67 million for the quarter, compared to analysts’ expectations of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same period last year, the firm earned ($0.41) EPS. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -0.9 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of RXRX. Vanguard Group Inc. increased its holdings in Recursion Pharmaceuticals by 18.6% in the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after buying an additional 7,407,606 shares during the last quarter. State Street Corp lifted its holdings in Recursion Pharmaceuticals by 38.7% during the 4th quarter. State Street Corp now owns 25,333,888 shares of the company’s stock worth $103,616,000 after buying an additional 7,064,963 shares during the last quarter. Norges Bank bought a new position in Recursion Pharmaceuticals during the 4th quarter worth approximately $23,473,000. ARK Investment Management LLC grew its position in shares of Recursion Pharmaceuticals by 11.2% in the 4th quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock worth $152,626,000 after acquiring an additional 3,771,357 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $7,370,000. Institutional investors own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

RXRX has been the topic of several recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen downgraded Recursion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. Morgan Stanley upped their target price on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Finally, JPMorgan Chase & Co. cut their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Recursion Pharmaceuticals has an average rating of “Hold” and an average price target of $8.10.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.